1-3 of 3
David Sedloev
Close
Sort by
Journal Articles

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Anna Mathioudaki, Xizhe Wang, David Sedloev, Richard Huth, Aryan Kamal, Michael Hundemer, Yi Liu, Spyridoula Vasileiou, Premal Lulla, Carsten Müller-Tidow, Peter Dreger, Thomas Luft, Tim Sauer, Michael Schmitt, Judith B. Zaugg, Caroline Pabst
Journal: Blood
Blood (2024) 143 (13): 1269–1281.
https://doi.org/10.1182/blood.2023021815
Published: 2024
Includes: Supplemental data
Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 5969.
https://doi.org/10.1182/blood-2023-181251
Published: 2023
Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney
Journal: Blood
Blood (2021) 138 (4): 318–330.
https://doi.org/10.1182/blood.2020008221
Published: 2021
Includes: Supplemental data